Understand the source comparison
5-Amino-1MQ Blood Work Labs Check Before After: Full Comparison
Triglycerides 150 mg/dL 105 mg/dL 95 mg/dL 37% reduction. Suggests enhanced lipid oxidation and VLDL clearance consistent with NNMT suppression Favourable metabolic response. Sustained reduction indicates effective enzyme inhibition HDL Cholesterol 48 mg/dL 52
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Triglycerides
- 150 mg/dL
- 105 mg/dL
- 95 mg/dL
- 37% reduction. Suggests enhanced lipid oxidation and VLDL clearance consistent with NNMT suppression
- Favourable metabolic response. Sustained reduction indicates effective enzyme inhibition
- HDL Cholesterol
- 48 mg/dL
- 52 mg/dL
- 55 mg/dL
- 15% increase. Improved reverse cholesterol transport, often accompanies triglyceride reduction
- Positive cardiovascular marker shift. Aligns with improved lipid metabolism
- LDL Cholesterol
- 135 mg/dL
- 128 mg/dL
- 120 mg/dL
- 11% reduction. Moderate decrease suggests overall lipid profile improvement
- Modest but consistent improvement. Clinically meaningful if sustained
- AST (liver enzyme)
- 28 U/L
- 34 U/L
- 31 U/L
- Transient mid-protocol elevation within normal range. Likely adaptive response
- No safety concern. Enzyme levels remain well within acceptable limits
- ALT (liver enzyme)
- 32 U/L
- 41 U/L
- 38 U/L
- Mild elevation at week 4, partial resolution by week 8. Monitor but not alarming
- Acceptable response pattern. Would warrant caution if exceeded 50 U/L
- hs-CRP
- 2.1 mg/L
- 1.4 mg/L
- 1.0 mg/L
- 52% reduction. Indicates decreased systemic inflammation
- Significant anti-inflammatory effect. Suggests metabolic health improvement beyond lipids
- Homocysteine
- 10.5 µmol/L
- 11.2 µmol/L
- 10.8 µmol/L
- Minimal change. Methylation capacity appears adequate despite NNMT inhibition
- No methylation pathway strain detected. Protocol is well-tolerated metabolically